The deleterious effects of iron overload in patients with myelodysplastic syndromes.

[1]  J. Bennett.  Consensus statement on iron overload in myelodysplastic syndromes , 2008, American journal of hematology.

[2]  T. Ganz,et al.  Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis , 2008, British journal of haematology.

[3]  E. Nemeth.  Iron regulation and erythropoiesis , 2008, Current opinion in hematology.

[4]  H. Leitch.  Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. , 2007, Leukemia research.

[5]  M. Cazzola,et al.  A Prognostic Model for Predicting the Impact of Comorbidities on Survival of Patients with Myelodysplastic Syndromes. , 2007 .

[6]  A. Stamatoullas,et al.  Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM. , 2007 .

[7]  Y. Eshet,et al.  No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique , 2007, American journal of hematology.

[8]  D. Pennell,et al.  Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions , 2007, British journal of haematology.

[9]  M. Tomonaga,et al.  Retrospective nationwide survey of Japanese patients with transfusion‐dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality , 2007, European journal of haematology.

[10]  S. Goldberg,et al.  P117 Prevalence of cardiac disease among a US medicare population with myelodysplastic syndromes , 2007 .

[11]  S. Goldberg,et al.  P001 Incidence of myelodysplastic syndromes in the United States medicare population , 2007 .

[12]  J. Porter,et al.  MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias. , 2006 .

[13]  R. Mertelsmann,et al.  Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. , 2006, Haematologica.

[14]  M. Cazzola,et al.  Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. , 2006, Haematologica.

[15]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Dimitrov,et al.  Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. , 2005, Leukemia research.

[17]  M. Cazzola,et al.  Myelodysplastic syndromes--coping with ineffective hematopoiesis. , 2005, The New England journal of medicine.

[18]  L. Ferrucci,et al.  Anemia and decline in physical performance among older persons. , 2003, The American journal of medicine.

[19]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[20]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[21]  M. Cazzola,et al.  Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. , 2002, Haematologica.

[22]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[23]  H. Krumholz,et al.  Blood transfusion in elderly patients with acute myocardial infarction. , 2001, The New England journal of medicine.

[24]  M. Cappellini,et al.  Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? , 2000, The hematology journal : the official journal of the European Haematology Association.

[25]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[26]  E. Greenberg,et al.  Newly delivered transferrin iron and oxidative cell injury , 1997, FEBS letters.

[27]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[28]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[29]  A. Tefferi,et al.  The 5q- syndrome: a single-institution study of 43 consecutive patients. , 1993, Blood.

[30]  P. Sadler,et al.  Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.

[31]  R. Gleason,et al.  Clinical consequences of acquired transfusional iron overload in adults. , 1981, The New England journal of medicine.

[32]  W. Roberts,et al.  Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.